Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging

Pharmacology and Therapeutics

Volumn 135, Issue 2, 2012, Pages 123-132

  Arjaans, Marlous ^a   Oude Munnink, Thijs H ^a   Timmer Bosscha, Hetty ^a   Reiss, Michael ^b   Walenkamp, Annemiek M E ^a   Lub De Hooge, Marjolijn N ^a   De Vries, Elisabeth G E ^a   Schröder, Carolina P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Imaging; TGF ; TGF activation; TGF inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 11014; BELAGENPUMATUCEL L; CILENGITIDE; ETARACIZUMAB; FRESOLIMUMAB; INTEGRIN; LY 2157299; MATRIX METALLOPROTEINASE; PLACEBO; SMALL MOLECULE TRANSPORT AGENT; TASISULUM; TEMOZOLOMIDE; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; CAUSE OF DEATH; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEVELOPED COUNTRY; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MELANOMA; METASTASIS; MOLECULAR IMAGING; NONHUMAN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SKIN CANCER; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84862638490     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.05.001     Document Type: Review

References (86)

1. Akhurst, R. J., & Derynck, R. (2001). TGF-β signaling in cancer - a double-edged sword. Trends Cell Biol 11, S44-S51.
2. Alexe, G., Dalgin, G. S., Ganesan, S., Delisi, C., & Bhanot, G. (2007). Analysis of breast cancer progression using principal component analysis and clustering. J Biosci 32, 1027-1039.
3. Aluwihare, P., Mu, Z., Zhao, Z., Yu, D., Weinreb, P. H., Horan, G. S., et al. (2009). Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J Cell Sci 122, 227-232.
4. Annes, J. P., Chen, Y., Munger, J. S., & Rifkin, D. B. (2004). Integrin αVβ6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1. J Cell Biol 165, 723-734.
5. Annes, J. P., Munger, J. S., & Rifkin, D. B. (2003). Making sense of latent TGF{beta} activation. J Cell Sci 116, 217-224.
6. Anscher, M. S., Marks, L. B., Shafman, T. D., Clough, R., Huang, H., Tisch, A., et al. (2001). Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol 19, 3758-3765.
7. Assoian, R. K., Komoriya, A., Meyers, C. A., Miller, D. M., & Sporn, M. B. (1983). Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 258, 7155-7160.
8. Bandyopadhyay, A., & Raghavan, S. (2009). Defining the role of integrin αvβ6 in cancer. Curr Drug Targets 10, 645-652.
9. Barcellos-Hoff, M. H., Derynck, R., Tsang, M. L., & Weatherbee, J. A. (1994). Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 93, 892-899.
10. Barcellos-Hoff, M., & Dix, T. (1996). Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 10, 1077-1083.
11. Baselga, J., Rothenberg, M. L., Tabernero, J., Seoane, J., Daly, T., Cleverly, A., et al. (2008). TGF-β signalling-related markers in cancer patients with bone metastasis. Biomarkers 13, 217-236.
12. Bierie, B., & Moses, H. L. (2006). Tumour microenvironment: TGFβ: the molecular jekyll and hyde of cancer. Nat Rev Cancer 6, 506-520.
13. Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., et al. (2007). Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117, 1305-1313.
14. Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K.,Mahapatra, A. K., Suri, A., et al. (2011). Targeted therapy for high-grade gliomawith the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13, 132-142.
15. Breuss, J., Gillett, N., Lu, L., Sheppard, D., & Pytela, R. (1993). Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem 41, 1521-1527.
16. Brooks, P. C., Strömblad, S., Sanders, L. C., von Schalscha, T. L., Aimes, R. T., Stetler-Stevenson, W. G., et al. (1996). Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 85, 683-693.
17. Brown, P. D., Wakefield, L. M., Levinson, A. D., & Sporn, M. B. (1990). Physicochemical activation of recombinant latent transforming growth factor-beta's 1,2, and 3. Growth Factors 3, 35-43.
18. Buck, M., der Fecht, J. V., & Knabbe, C. (2002). Antiestrogenic regulation of transforming growth factor beta receptors I and II in human breast cancer cells. Ann N Y Acad Sci 963, 140-143.
19. Calvo-Aller, E., Baselga, J., Glatt, S., Cleverly, A., Lahn, M., Arteaga, C. L., et al. (2008). First human dose escalation study in patient with metastatic malignancies to determine safety and pharmacokinteics of LY2157299, a small molecule inhibitor of the transforming growth factor factor-beta receptor kinase I. J Clin Oncol 26 (Abstract#14554).
20. Chiang, A. C., & Massagué, J. (2008). Molecular basis of metastasis. N Engl J Med 359, 2814-2823.
21. Dallas, S. L., Miyazono, K., Skerry, T. M., Mundy, G. R., & Bonewald, L. F. (1995). Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 131, 539-549.
22. Derynck, R., Lindquist, P. B., Lee, A., Wen, D., Tamm, J., Graycar, J. L., et al. (1998). A new type of transforming growth factor-beta, TGF-beta 3. EMBO J 7, 3737-3743.
23. Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., et al. (2007). Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13, 3207-3214.
24. Dubois, C. M., Laprise, M., Blanchette, F., Gentry, L. E., & Leduc, R. (1995). Processing of transforming growth factor 1 precursor by human furin convertase. J Biol Chem 270, 10618-10624.
25. Ehata, S., Hanyu, A., Fujime, M., Katsuno, Y., Fukunaga, E., Goto, K., et al. (2007). Ki26894, a novel transforming growth factor-β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98, 127-133.
26. Farrington, D. L., Yingling, J. M., Fill, J. A., Yan, L., Qian, Y., Shou, J., et al. (2007). Development and validation of a phosphorylated SMAD ex vivo stimulation assay. Biomarkers 12, 313-330.
27. Flaumenhaft, R., & Rifkin, D. B. (1992). The extracellular regulation of growth factor action. Mol Biol Cell 3, 1057-1065.
28. Ganapathy, V., Ge, R., Grazioli, A., Xie, W., Banach-Petrosky, W., Kang, Y., et al. (2010). Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 9, 122.
29. Ge, R., Rajeev, V., Ray, P., Lattime, E., Rittling, S., Medicherla, S., et al. (2006). Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res 12, 4315-4330.
30. Giampieri, S., Manning, C., Hooper, S., Jones, L., Hill, C. S., & Sahai, E. (2009). Localized and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 11, 1287-1296.
31. Goudie, D. R., D'Alessandro, M., Merriman, B., Lee, H., Szeverényi, I., Avery, S., et al. (2011). Multiple self-healing squamous epithelioma is caused by a diseasespecific spectrum of mutations in TGFBR1. Nat Genet 43, 365-369.
32. Gray, A. M., & Mason, A. J. (1990). Requirement for activin A and transforming growth factor-β1 pro-regions in homodimer assembly. Science 247, 1328-1330.
33. Hersey, P., Sosman, J., O'Day, S., Richards, J., Bedikian, A., Gonzalez, R., et al. (2010). A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma. Cancer 116, 1526-1534.
34. Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., et al. (2008). Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 177, 56-65.
35. Kanzaki, T., Olofsson, A., Morén, A., Wernstedt, C., Hellman, U., Miyazono, K., et al. (1990). TGF-β1 binding protein: a component of the large latent complex of TGF-β1 with multiple repeat sequences. Cell 61, 1051-1061.
36. Kareddula, A., Zachariah, E., Notterman, D., & Reiss, M. (2008). Transforming growth factor-β signaling strength determines target gene expression profile in human keratinocytes. J Epithelial Biol Pharmacol 1, 40-94.
37. Khalil, N. (1999). TGF-β: from latent to active. Microbes Infect 1, 1255-1263.
38. Kirshner, J., Jobling, M. F., Pajares, M. J., Ravani, S. A., Glick, A. B., Lavin, M. J., et al. (2006). Inhibition of transforming growth factor-β1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res 66, 10861-10869.
39. Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D. A., & Kang, Y. (2009). Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 15, 1960-1966.
40. Lawrence, D. A., Pircher, R., & Jullien, P. (1985). Conversion of a high molecular weight latent β-TGF from chicken embryo fibroblasts into a low molecular weight active β-TGF under acidic conditions. Biochem Biophys Res Commun 133, 1026-1034.
41. Levy, L., & Hill, C. S. (2006). Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17, 41-58.
42. Lvshina, A. V., George, J., Senko, O., Mow, B., Putti, T. C., Smeds, J., et al. (2006). Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66, 10292-10301.
43. Lyons, R. M., Keski-Oja, J., & Moses, H. L. (1988). Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol 106, 1659-1665.
44. Massagué, J. (2008). TGFβ in cancer. Cell 134, 215-230.
45. Massagué, J., Blain, S. W., & Lo, R. S. (2000). TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309.
46. Melisi, D., Ishiyama, S., Sclabas, G. M., Fleming, J. B., Xia, Q., Tortora, G., et al. (2008). LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7, 829-840.
47. Miyazono, K., Olofsson, A., Colosetti, P., & Heldin, C. H. (1991). A role of the latent TGFbeta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J 10, 1091-1101.
48. Morris, J., Shapiro, G., Tan, A. R., Lawrence, D. P., Olencki, T. E., Dezube, B. J., et al. (2008). Phase 1/2 study of GC1008: amonoclonal antibody (MAb) in patients with advanced malignant melanoma or renal cell carcinoma. J Clin Oncol 26 (Abstract#9028).
49. Moustakas, A., & Heldin, C. (2005). Non-smad TGF-beta signals. J Cell Sci 118, 3573-3584.
50. Munger, J. S., Harpel, J. G., Gleizes, P. E., Mazzieri, R., Nunes, I., & Rifkin, D. B. (1997). Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int 51, 1376-1382.
51. Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., et al. (1999). A mechanism for regulating pulmonary inflammation and fibrosis: the integrin αvβ6 binds and activates latent TGF β1. Cell 96, 319-328.
52. Nagengast, W. B., de Korte, M. A., Oude Munnink, T. H., Timmer-Bosscha, H., den Dunnen, W. F., Hollema, H., et al. (2010). 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 51, 761-767.
53. Nagengast, W. B., de Vries, E. G., Hospers, G. A., Mulder, N. H., de Jong, J. R., Hollema, H., et al. (2007). In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48, 1313-1319.
54. Nam, J., Suchar, A. M., Kang, M., Stuelten, C. H., Tang, B., Michalowska, A. M., et al. (2006). Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor β in a mouse model of breast cancer. Cancer Res 66, 6327-6335.
55. Nemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., et al. (2006). Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non small-cell lung cancer. J Clin Oncol 24, 4721-4730.
56. Nemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., et al. (2009). Phase II trial of belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 16, 620-624.
57. Nishi, H., Nakada, T., Hokamura, M., Osakabe, Y., Itokazu, O., Huang, L. E., et al. (2004). Hypoxia-inducible factor-1 transactivates transforming growth factor-beta 3 in trophoblasts. Endocrinology 145, 4113-4118.
58. Noordhuis, M. G., Fehrmann, R. S. N., Wisman, G. B. A., Nijhuis, E. R., van Zanden, J. J., Moerland, P. D., et al. (2011). Involvement of the TGF-β and β-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res 17, 1317-1330.
59. 89Zr labeled transforming growth factor (TGF)-β antibody fresolimumab in tumor models. J NuclMed 52, 2001-2008.
60. Padua, D., & Massague, J. (2009). Roles of TGF-beta in metastasis. Cell Res 19, 89-102.
61. Padua, D., Zhang, X. H., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., et al. (2008). TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77.
62. Pinkas, J., & Teicher, B. A. (2006). TGF-β in cancer and as a therapeutic target. Biochem Pharmacol 72, 523-529.
63. Puthawala, K., Hadjiangelis, N., Jacoby, S. C., Bayongan, E., Zhao, Z., Yang, Z., et al. (2008). Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 177, 82-90.
64. Reiss, M., & Barcellos-Hoff, M. H. (1997). Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45, 81-95.
65. Riethdorf, S., Wikmam, H., & Pantel, K. (2008). Review: biological relevance of disseminated tumor cells in cancer patient. Int J Cancer 123, 1991-2006.
66. Rodon Ahnert, J., Baselga, J., Calvo, E., Seoane, J., Brana, I., Sicart, E., et al. (2011). First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. J Clin Oncol 29 (Abstract #3011).
67. Saunier, E. F., & Akhurst, R. J. (2006). TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 6, 565-578.
68. Shi, Y., & Massagué, J. (2003). Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700.
69. Stover, D. G., Bierie, B., & Moses, H. L. (2007). A delicate balance: TGF-beta and the tumor microenvironment. J Cell Biochem 101, 851-861.
70. Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., et al. (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28, 2712-2718.
71. Tabatabai, G., Weller, M., Nabors, B., Picard, M., Reardon, D., Mikkelsen, T., et al. (2010). Targeting integrins in malignant melanoma. Target Oncol 5, 175-181.
72. Taipale, J., Miyazono, K., Heldin, C., & Keski-Oja, J. (1994). Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol 124, 171-181.
73. Tan, A. R., Alexe, G., & Reiss, M. (2009). Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat 115, 453-495.
74. Tucker, G. C. (2006). Integrins: molecular targets in cancer therapy. Curr Oncol Rep 8, 96-103.
75. van Aarsen, L. A., Leone, D. R., Ho, S., Dolinski, B. M., McCoon, P. E., LePage, D. J., et al. (2008). Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res 68, 561-570.
76. Vujaskovic, Z., Marks, L. B., & Anscher, M. S. (2000). The physical parameters and molecular events associated with radiation-induced lung toxicity. Semin Radiat Oncol 10, 296-307.
77. Weigert, C., Brodbeck, K., Häring, H. U., Gambaro, G., & Schleicher, E. D. (2001). Low-molecular- weight heparin prevents high glucose- and phorbolester-induced TGFbeta 1 gene activation. Kidney Int 60, 935-943.
78. Welch, D. R., Fabra, A., & Nakajima, M. (1990). Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci 87, 7678-7682.
79. Wipff, P., & Hinz, B. (2008). Integrins and the activation of latent transforming growth factor β1 - an intimate relationship. Eur J Cell Biol 87, 601-615.
80. Wipff, P., Rifkin, D. B., Meister, J., & Hinz, B. (2007). Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J Cell Biol 179, 1311-1323.
81. Worthington, J. J., Klementowicz, J. E., & Travis, M. A. (2011). TGFβ: a sleeping giant awoken by integrins. Trends Biochem Sci 36, 47-54.
82. Wyckoff, J. B., Jones, J. G., Condeelis, J. S., & Segall, J. E. (2000). A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res 60, 2504-2511.
83. Xu, M. Y., Porte, J., Knox, A. J., Weinreb, P. H., Maher, T. M., Violette, S. M., et al. (2009). Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 174, 1264-1279.
84. Yu, Q., & Stamenkovic, I. (1999). Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13, 35-48.
85. Yu, Q., & Stamenkovic, I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 14, 163-176.
86. Zhao, L., Sheldon, K., Chen, M., Yin, M. S., Hayman, J. A., Kalemkerian, G. P., et al. (2008). The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 59, 232-239.